If you have been reading about Cardarine and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-11-07. Numbers and descriptions here follow the published literature rather than marketing material.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
| Property | Value | Notes |
|---|---|---|
| Solubility | Soluble in dimethyl sulfoxide and some organic solvents; practically insoluble in water | Solvent choice affects laboratory handling |
| Typical storage | -20 °C, desiccated, protected from light | Common condition for research samples |
| Analytical method | Liquid chromatography–tandem mass spectrometry (LC-MS/MS) | Used for identification and quantification in biological or product samples |
| Common synonyms | GW501516, GW-501516, GSK-516, Endurobol | Names found in research and anti-doping literature |
| Regulatory status | Unapproved therapeutic; prohibited in competitive sport | Status can vary by country and context |
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
=== June === 6 June MPs vote to suspend Margaret Ferrier, the MP for Rutherglen and Hamilton West, from the House of Commons for 30 days for breaching COVID-19 regulations, almost certainly triggering a by-election in her constituency. Kevin Stewart resigns as Minister for Transport after experiencing poor mental health. 7 June – Circular Economy Minister Lorna Slater confirms that Scotland's Deposit Return Scheme is to be delayed until at least October 2025, meaning it will launch at a similar time to similar projects in other parts of the UK. 8 June – Members of the National Union of Rail, Maritime and Transport Workers at ScotRail vote to accept a 5% pay increase for 2023–24. 11 June – Police Scotland arrest former First Minister Nicola Sturgeon as part of their ongoing investigation into the SNP's finances. She is subsequently released without charge. 12 June – First Minister Humza Yousaf tells BBC News he will not suspend Nicola Sturgeon from the SNP following her arrest. 13 June BMA Scotland announces that junior doctors have rejected a 14.5% pay offer from the Scottish Government and will stage a 72-hour strike from 12 to 15 July. Màiri McAllan, Scotland's Cabinet Secretary for Net Zero and Just Transition, is additionally appointed as Minister for Transport, replacing Kevin Stewart in the role. 14 June – Jo Farrell, the current Chief Constable of Durham Constabulary, is appointed as Police Scotland's first female Chief Constable; she will replace Sir Iain Livingstone, who retires in August.
== Sex identification == The 2002 report on the grave had reported that "This is the only known Iron Age grave to contain both a sword and mirror, raising interesting questions as to the gender significance of both these grave goods", but that "preservation of bone and DNA was too poor to determine the person's sex". A 2016 paper said that "Their combined presence within the burial of a single individual represents a touchstone within the ongoing unraveling of a long-held, interconnected set of reified sex and gender assumptions that have permeated discussions of British Iron Age mortuary contexts" and that "Hillside Farm as a starting point highlights the need to keep in mind the potential significance of any aspect of the burial, not to deny that men and women may have existed, or that certain artifacts may have conveyed a gendered meaning, but to refrain from excluding other routes to identity, personhood, or significance before analysis begins." In 2023, American scientists used new techniques of analysis of dental peptides, which indicated that, with 96% probability, the person in the grave was female.
== Diagnosis == The diagnosis of OSA syndrome is made when the patient has recurrent episodes of partial or complete collapse of the upper airway during sleep, resulting in apneas or hypopneas, respectively. Criteria defining an apnea or a hypopnea vary. The American Academy of Sleep Medicine (AASM) defines an apnea episode as a reduction in airflow of ≥ 90% lasting at least 10 seconds. A hypopnea is defined as a reduction in airflow of ≥ 30% lasting at least 10 seconds and associated with a ≥ 4% decrease in pulse oxygenation, or as a ≥ 30% reduction in airflow lasting at least 10 seconds and associated either with a ≥ 3% decrease in pulse oxygenation or with an arousal. To define the severity of the condition, the Apnea-Hypopnea Index (AHI) or the Respiratory Disturbance Index (RDI) is used. While the AHI measures the mean number of apneas and hypopneas per hour of sleep, the RDI adds to this measure the respiratory effort-related arousals (RERAs). The OSA syndrome is thus diagnosed if the AHI is > 5 episodes per hour and results in daytime sleepiness and fatigue or when the RDI is ≥ 15 independently of the symptoms. Daytime sleepiness may be classified as mild, moderate, or severe depending on its impact on social life. Daytime sleepiness can be assessed using the Epworth Sleepiness Scale (ESS), a self-reported questionnaire on the propensity to fall asleep or doze off during the day. Screening tools for OSA itself comprise the STOP questionnaire, the Berlin questionnaire and the STOP-BANG questionnaire which has been reported as being a powerful tool to detect OSA.
Anastrozole, sold under the brand name Arimidex among others, is an antiestrogenic medication used in addition to other treatments for breast cancer. Specifically it is used for hormone receptor-positive breast cancer. It has also been used to prevent breast cancer in those at high risk. It is taken orally. Common side effects of anastrozole include hot flashes, altered mood, joint pain, and nausea. Severe side effects include an increased risk of heart disease and osteoporosis. Use during pregnancy may harm the fetus. Anastrozole is in the aromatase-inhibiting family of medications. It works by blocking the production of estrogens in the body, and hence has antiestrogenic effects. Anastrozole was patented in 1987 and was approved for medical use in 1995. It is on the World Health Organization's List of Essential Medicines. Anastrozole is available as a generic medication. In 2023, it was the 194th most commonly prescribed medication in the United States, with more than 2 million prescriptions.
Sources: en.wikipedia.org
gluconeogenesis (GNG) The chain of metabolic reactions that results in the generation of glucose from some non-carbohydrate carbon substrates, including the glucogenic amino acids. It is one of two primary pathways used by most animals to maintain blood sugar levels (the other being glycogenolysis), especially during periods of fasting, starvation, and intense exercise.
== Legislation == The plight of patients with rare diseases became an important political issue in the late 1970s and early 1980s. The US government was subject to pressure from activist groups such as NORD and many others. The chief sponsor of the bill (H.R. 5238) was Henry Waxman (sometimes referred to as the author of the Act), chairman of the Energy and Commerce Subcommittee on Health. It passed the House of Representatives on 14 December 1982, and was similarly approved by voice vote in the Senate on 17 December. On 4 January 1983, President Ronald Reagan signed the ODA into law. Under the ODA drugs, vaccines, and diagnostic agents would qualify for orphan status if they were intended to treat a disease affecting less than 200,000 American citizens. In order to encourage the development of drugs for orphan diseases, the ODA included a number of incentives including seven-year market exclusivity for companies that developed orphan drug, tax credits equal to half of the development costs, later changed to a fifteen-year carry-forward provision and a three-year carry-back that can be applied in profitable year, grants for drug development, fast-track approvals of drugs indicated for rare diseases, and expanded access to the Investigational New Drug Program. The law was also later amended to waive user fees charged under PDUFA. Market exclusivity is particularly appealing to pharmaceutical firms as an incentive to pursue orphan drug development.
The niacin test has been widely used since the 1960s to identify mycobacteria at the species level in the clinical laboratory. The niacin test detects niacin (nicotinic acid) in aqueous extracts of a culture. M. tuberculosis strains that test negative for the niacin test are very rare. Redox reactions happening in Mycobacterium species produce niacin as a part of energy metabolism. Even though all mycobacteria produce niacin, M. tuberculosis accumulates an excess of niacin because of its inability to process niacin, excreting the excess niacin into the culture media, thus allowing it to be detected using the niacin test. The niacin test is typically only conducted on slow-growing, granular, tan colored colonies, as these are the morphology characteristics of M. tuberculosis on an agar plate. Because of its affordability compared to expensive identification methods like pyrosequencing or MALDI-TOF MS that require expensive machines and reagents.
Sources: en.wikipedia.org
Similarly, a base such as spermine has more than one site where protonation can occur. For example, mono-protonation can occur at a terminal −NH2 group or at internal −NH− groups. The Kb values for dissociation of spermine protonated at one or other of the sites are examples of micro-constants. They cannot be determined directly by means of pH, absorbance, fluorescence or NMR measurements; a measured Kb value is the sum of the K values for the micro-reactions.
== Track listing == "Sickman", "Junkhead", "Dirt" and "God Smack" are credited to Cantrell/Staley with no specification for lyrics or music. "Rain When I Die" is credited to Cantrell/Staley/Kinney/Starr, and it was later stated that Cantrell and Staley wrote the lyrics.
The Wagler's pit viper is sexually dimorphic: the females grow to approximately 1 m (39+1⁄4 in) in total length (including tail), their bodies being black with yellow stripes. Males, on the other hand, typically do not exceed 75 cm (29+1⁄2 in). Males have large triangular-shaped heads, with relatively thin green bodies. They are almost entirely arboreal, and their tails are prehensile to aid in climbing. They are found in a wide variety of colors and patterns, often referred to as "phases". In the past, some researchers classified the different phases as subspecies. The phases vary greatly from having a black or brown coloration as a base, with orange and yellow banding, to others having a light green as the base color, with yellow or orange banding, and many variations therein.
Sources: en.wikipedia.org
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.
No. It is not an anabolic-androgenic steroid; it is a synthetic PPARδ agonist. Because it is banned in sport, it is sometimes grouped with doping agents even though its chemical class differs from steroids.
Human data are limited and development was discontinued, so major effects and long-term risks are not well characterized. Some early studies examined metabolic markers, but they do not provide a basis for unsupervised use.
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.